Century Therapeutics (IPSC) Accumulated Expenses (2020 - 2026)

Century Therapeutics (IPSC) has reported Accumulated Expenses for 7 consecutive years, with $8.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 187.94% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (up 187.94% YoY), while the FY2025 annual figure was $11.7 million, down 33.13% from the prior year.
• Accumulated Expenses fell to $8.5 million in Q1 2026 per IPSC's latest filing, from $11.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $17.5 million in Q4 2024 and bottomed at $721000.0 in Q3 2022.
• Historically, Accumulated Expenses has averaged $7.9 million across 5 years, with a median of $7.2 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 90.07% — and 2023, when it soared 1277.53%.
• Century Therapeutics' Accumulated Expenses stood at $7.1 million in 2022, then declined by 8.01% to $6.5 million in 2023, then jumped by 168.8% to $17.5 million in 2024, then slumped by 33.13% to $11.7 million in 2025, then slipped by 27.4% to $8.5 million in 2026.
• Business Quant data shows IPSC's Accumulated Expenses at $8.5 million in Q1 2026, $11.7 million in Q4 2025, and $11.1 million in Q3 2025.